Search for Clinical Trial Results

Sponsored By

Granulomatosis with Polyangiitis - 50 Studies Found

Status Study
Recruiting Study Name: Rituximab in Eosinophilic Granulomatosis With Polyangiitis
Condition: Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Date: 2016-05-20
Interventions:
  • Drug: Rituximab 1 g intravenou
Recruiting Study Name: Determining Disease Activity Biomarkers in Individuals With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
Condition:
  • Eosinophilic Granulomatosis With Polyangiitis
  • Churg-Strauss Syndrome
    Date: 2016-09-26
Completed Study Name: A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
Condition: Churg-Strauss Syndrome
Date: 2013-12-19
Interventions:
  • Biological: Mepolizumab Mepoli
Completed Study Name: Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome
Condition: Churg Strauss Syndrome
Date: 2007-09-07
Interventions: Biological: Mepolizumab IV mepolizumab, 750 mg Other
Terminated Study Name: Rituxan in Churg Strauss Syndrome With Renal Involvement
Condition: Churg-Strauss Syndrome
Date: 2007-01-19
Interventions:
  • Drug: Rituximab Patients recei
Terminated Study Name: CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors
Condition: Churg-Strauss Syndrome
Date: 2006-11-13
Interventions:
  • Drug: azathioprine
  • Drug: cyclophosphamide
Completed Study Name: Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome
Condition: Churg Strauss Syndrome
Date: 2008-07-14
Interventions: Drug: mepolizumab 750 mg mepolizumab iv q4wk until week 32
Not yet recruiting Study Name: Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome
Condition: Churg-Strauss Syndrome
Date: 2016-03-14
Interventions: Biological: HPC cell infusion Administration of total lymp
Not yet recruiting Study Name: Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Condition: Asthma
Date: 2016-10-17
Interventions: Drug: Reslizumab All subjects will receive Reslizumab
Next >>>